LONG-TERM DEBT (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands							1 Months Ended	12 Months Ended
	May 17, 2021	Feb. 03, 2021	May 22, 2020	Jan. 31, 2019	Jul. 17, 2018	Dec. 06, 2016	May 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Jul. 21, 2020	May 06, 2016
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount								$ 2,000
Debt conversion, converted instrument, additional amount								2,000
Exercise price of warrant											$ 3.34
Effective price of warrants			$ 1.52
Intrinsic value of beneficial conversion feature recorded to additional paid in capital			$ 2,577
Long term debt								32,224
Amortization of debt issuance costs								2,999	1,569
Amortization of debt discount								$ 1,838
Related Party [Member]
Debt Instrument [Line Items]
Amortization of debt issuance costs									461
Interest expense related party									723
Perceptive Credit Holdings LP [Member]
Debt Instrument [Line Items]
Debt instrument maturity date								Jun. 30, 2020
Debt issuance cost						$ 360
Debt discount						3,453
Proceeds from related party								$ 14,500
Loss on extinguishment of debt								84
Credit facility						1,800						$ 6,000
Commitment amount						13,200
Proceeds from warrants						2,793
Debt exit fees						$ 300
Restated K2 Warrant [Member]
Debt Instrument [Line Items]
Additional unamortized discount	$ 1,721
Fair value adjustment of warrants	867
Warrant One [Member] | Perceptive Credit Holdings LP [Member]
Debt Instrument [Line Items]
Exercise price of warrant						$ 4.13
Warrants issued to purchase shares						363,771
Warrant Two [Member] | Perceptive Credit Holdings LP [Member]
Debt Instrument [Line Items]
Exercise price of warrant						$ 3.355
Warrants issued to purchase shares						1,341,282
K 2 Healthventures L L C [Member]
Debt Instrument [Line Items]
Amortization of debt issuance costs								$ 1,161
Second Tranche [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Additional discount	834
Second Tranche [Member] | Restated K2 Warrant [Member]
Debt Instrument [Line Items]
Debt issuance cost	$ 20
Loan and Guaranty Agreement [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Jun. 01, 2024	Jun. 01, 2024
Debt instrument, interest rate, stated percentage								8.25%
Secured term loan final payment percentage										6.95%
Final payment								$ 2,224
Loans Payable								$ 30,000
Debt increased in rate of interest								5.00%
Loan and Guaranty Agreement [Member] | Final Payment [Member]
Debt Instrument [Line Items]
Debt instrument, effective interest rate percentage								15.33%
Loan and Guaranty Agreement [Member] | K2 Warrant [Member]
Debt Instrument [Line Items]
Exercise price of warrant			$ 1.12
Warrants issued to purchase shares			625,000
Loan and Guaranty Agreement [Member] | Restated K2 Warrant [Member]
Debt Instrument [Line Items]
Exercise price of warrant	$ 1.12
Warrants issued to purchase shares	312,500
Loan and Guaranty Agreement [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage								5.00%
Loan and Guaranty Agreement [Member] | K 2 Healthventures L L C [Member]
Debt Instrument [Line Items]
Debt description			The Lenders originally agreed to make available the following additional tranches subject to the following conditions and upon the submission of a loan request by the Company: (1) up to $10,000 available between January 1, 2021 and April 30, 2021 upon achievement of certain milestones (the “Second Tranche Term Loan”), (2) $10,000 available between the closing date and December 31, 2021, subject to achievement of a certain U.S. Food and Drug Administration (“FDA”) approval (the “Third Tranche Term Loan”), and (3) a final tranche of up to $10,000 that can be made available any time prior to June 30, 2022,  subject to the advance of the Third Tranche Term Loan, satisfactory review by the administrative agent of our financial and operating plan, and approval by the Lenders’ investment committee (the “Fourth Tranche Term Loan”). The Company obtained the FDA approval on November 30, 2021 but elected not to draw down the Third Tranche Term Loan. Pursuant to the Loan Agreement, the Lenders originally had the ability to convert, at the Lenders’ option, up to $4,000 of the secured term loan into common shares of the Company at a conversion price of $1.46 per share (“K2 conversion feature”) until the maturity date of June 1, 2024
Debt conversion, converted instrument, amount			$ 4,000
Debt instrument, convertible, conversion price			$ 1.46
Debt instrument maturity date			Jun. 01, 2024
Purchase of warrants	937,500
Debt issuance cost			$ 1,021
Additional discount			1,390
Debt discount			$ 6,169
Loan and Guaranty Agreement [Member] | K 2 Healthventures L L C [Member] | K2 Warrant [Member]
Debt Instrument [Line Items]
Purchase of warrants			625,000
Exercise price of warrant			$ 1.12
Warrant or right, reason for issuance, description			The number of common shares issuable pursuant to the Restated K2 Warrant, at any given time, is determined by dividing the Warrant Coverage Amount by the Warrant Price, where the Warrant Coverage Amount is equal to the sum of $1,050 plus the aggregate original principal amount of the Third Tranche and Fourth Tranche Term Loan advanced at that time multiplied by 3.5%. The Restated K2 Warrant may be exercised either for cash or on a cashless “net exercise” basis and expires on May 22, 2030
Warrant maturity date			May 22, 2030
Allocation of warrants to additional paid in capital			$ 1,181
Loan and Guaranty Agreement [Member] | K 2 Healthventures L L C [Member] | Restated K2 Warrant [Member]
Debt Instrument [Line Items]
Purchase of warrants	312,500
Exercise price of warrant	$ 1.12
Debt instrument, face amount	$ 1,050
Loan and Guaranty Agreement [Member] | First Tranche [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage								8.25%
Loan and Guaranty Agreement [Member] | First Tranche [Member] | K 2 Healthventures L L C [Member]
Debt Instrument [Line Items]
Secured debt			20,000
Loan and Guaranty Agreement [Member] | Second Tranche [Member]
Debt Instrument [Line Items]
Secured debt			10,000
Debt instrument, interest rate, stated percentage	7.75%							7.75%
Debt issuance cost	$ 20
Secured term loan final payment percentage	6.95%
Additional discount	$ 834
Third party cost	$ 150
Loan and Guaranty Agreement [Member] | Second Tranche [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	4.50%							4.50%
Loan and Guaranty Agreement [Member] | Second Tranche [Member] | Minimum [Member]
Debt Instrument [Line Items]
Secured debt	$ 10,000
Debt instrument, date of first required payment	Jul. 01, 2022
Loan and Guaranty Agreement [Member] | Second Tranche [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured debt	$ 12,000
Debt instrument, date of first required payment	Jan. 01, 2023
Loan and Guaranty Agreement [Member] | Third Tranche [Member]
Debt Instrument [Line Items]
Secured debt			10,000
Debt instrument interest period extended date								Jan. 01, 2023
Loan and Guaranty Agreement [Member] | Final Tranche [Member] | K 2 Healthventures L L C [Member]
Debt Instrument [Line Items]
Secured debt			$ 10,000
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt discount								$ 3,783	5,061
Loan Agreement [Member] | K 2 Healthventures L L C [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount		$ 2,000
Debt instrument, convertible, conversion price		$ 1.46
Debt conversion, converted instrument, shares issued		1,369,863
Debt instrument, call feature								The Lenders have the ability to convert an additional $2,000 at the Lenders’ option
Debt discount								$ 7,890	$ 6,169
Second Amendment [Member]
Debt Instrument [Line Items]
Debt description					the Company amended the Amended Credit Facility (the “Second Amendment”) to extend the period the Company is required to pay only the interest on the loan from May 31, 2018 to December 31, 2018 and to extend the expiration date of certain warrants to purchase 363,771 common shares issued to Perceptive with an original expiration date of July 25, 2019 to December 6, 2021
Debt discount					$ 386
Warrants issued to purchase shares					363,771
Third Amendment [Member]
Debt Instrument [Line Items]
Debt description				the Company further amended the Amended Credit Facility (the “Third Amendment”) to i) extend the period the Company is required to pay only the interest on the loan from December 31, 2018 to January 31, 2020, ii) extend the maturity of the term loan to June 30, 2020, and iii) reduce the exercise price on certain warrants to purchase common shares issued to Perceptive to $2.75 from $4.13 for 363,771 warrants issued on July 25, 2014, and for 363,771 warrants issued on December 6, 2016, and from $3.355 for 1,341,282 warrants issued on December 6, 2016
Debt discount				$ 179
Third Amendment [Member] | Warrant One [Member]
Debt Instrument [Line Items]
Exercise price of warrant				$ 2.75		$ 4.13
Warrants issued to purchase shares						363,771
Third Amendment [Member] | Warrant Two [Member]
Debt Instrument [Line Items]
Exercise price of warrant						$ 3.355
Warrants issued to purchase shares						1,341,282